glp-1 analog weight loss Glucagon-like peptide-1 receptor agonists and muscle mass effects GLP-1-directed NMDA receptor antagonism for

A comprehensive meta-analysis of randomised controlled trials examining GLP-1 receptor agonists found no significant increase in overall cancer incidence compared to placebo or active comparators

When combined with Wegovywhich is specifically designed to reduce appetite and food consumptionthere is a theoretical risk of excessive caloric restriction, potentially leading to nutritional deficiencies, muscle loss, or other adverse metabolic effects

Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer

Now, that may not be the end of the world, but it is something to really consider